Given that aCD3 cultures favored venetoclax resistance by the upregulation of BCL-XL and MCL-1 in CLL cells (11, 12), we wondered whether SPHK inhibitors are able to impair the upregulation of these proteins. Here, BCL2L1 is linked to B-cell chronic lymphocytic leukemia.